Pamidronate or Zoledronic Acid (Zometa™) are routinely used for hypercalcaemia associated with cancer and is increasingly used regularly as a prophylactic treatment in patients with Multiple Myeloma, Breast Cancer, and Prostate Cancer to reduce the risk of pain, fracture and other skeletal events.
For patients with metastatic bone disease, the use of 90 mg of pamidronate IV over 2-4 hours may improve acute bone pain (check first with an Oncologist/ Palliative Care Specialist).
Information about this Canterbury DHB document (4077):